What is Corvus Pharmaceu's earnings per share (EPS)?

Corvus Pharmaceu (CRVS) reported diluted earnings per share of $-0.53 for fiscal year 2025. This represents a 48.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Corvus Pharmaceu Financials

CRVS

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Corvus Pharmaceu (CRVS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

Corvus Pharmaceu passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

2.15x

For every $1 of reported earnings, Corvus Pharmaceu generates $2.15 in operating cash flow (-$32.8M OCF vs -$15.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$42.9M

YoY-56.1%

Corvus Pharmaceu's EBITDA was -$42.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 56.1% from the prior year.

Net Income

-$15.3M

YoY+75.5%

Corvus Pharmaceu reported -$15.3M in net income in fiscal year 2025. This represents an increase of 75.5% from the prior year.

EPS (Diluted)

$-0.53

YoY+48.0%

Corvus Pharmaceu earned $-0.53 per diluted share (EPS) in fiscal year 2025. This represents an increase of 48.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$33.0M

Corvus Pharmaceu generated -$33.0M in free cash flow in fiscal year 2025, representing cash available after capex.

Cash & Debt

$4.6M

YoY-47.6%

5Y CAGR-22.6%

10Y CAGR+1.1%

Corvus Pharmaceu held $4.6M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

75M

YoY+10.0%

5Y CAGR+21.4%

Corvus Pharmaceu had 75M shares outstanding in fiscal year 2025. This represents an increase of 10.0% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-25.0%

YoY+166.3pp

5Y CAGR-16.7pp

Corvus Pharmaceu's ROE was -25.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 166.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$33.7M

YoY+73.9%

5Y CAGR+1.2%

10Y CAGR+11.5%

Corvus Pharmaceu invested $33.7M in research and development in fiscal year 2025. This represents an increase of 73.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$174K

5Y CAGR+18.0%

10Y CAGR-20.6%

Corvus Pharmaceu invested $174K in capex in fiscal year 2025, funding long-term assets and infrastructure.

CRVS Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$33.7M+73.9%	$19.4M+17.3%	$16.5M-32.5%	$24.5M-16.0%	$29.1M-8.5%	$31.8M
SG&A Expenses	$9.3M+13.3%	$8.2M+18.6%	$6.9M-15.0%	$8.1M-14.9%	$9.5M-20.2%	$11.9M
Operating Income	-$43.0M-56.0%	-$27.5M-17.7%	-$23.4M+28.1%	-$32.6M+15.7%	-$38.6M+11.7%	-$43.8M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$15.3M+75.5%	-$62.3M-130.5%	-$27.0M+34.6%	-$41.3M+4.5%	-$43.2M-621.3%	-$6.0M
EPS (Diluted)	$-0.53+48.0%	$-1.02-82.1%	$-0.56+37.1%	$-0.89+13.6%	$-1.03-415.0%	$-0.20

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$8.5M+7.4%	$7.9M+5.6%	$7.5M	N/A	$5.2M+26.9%	$4.1M+1.0%	$4.1M
SG&A Expenses	N/A	$2.1M-11.3%	$2.4M-3.3%	$2.5M	N/A	$2.0M+11.6%	$1.8M-16.4%	$2.2M
Operating Income	N/A	-$10.6M-3.0%	-$10.3M-3.4%	-$9.9M	N/A	-$7.3M-22.2%	-$5.9M+5.1%	-$6.3M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Net Income	N/A	-$10.2M-27.0%	-$8.0M-152.6%	$15.2M	N/A	-$40.2M-843.6%	-$4.3M+25.2%	-$5.7M
EPS (Diluted)	N/A	$-0.12-20.0%	$-0.10+23.1%	$-0.13	N/A	$-0.60-757.1%	$-0.07+41.7%	$-0.12

CRVS Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$71.1M+3.2%	$68.9M+51.3%	$45.6M-33.2%	$68.2M-37.7%	$109.5M+28.0%	$85.5M
Current Assets	$58.2M+7.0%	$54.4M+94.6%	$28.0M-36.0%	$43.7M-38.8%	$71.3M+57.3%	$45.3M
Cash & Equivalents	$4.6M-47.6%	$8.7M-30.7%	$12.6M-4.1%	$13.2M-79.3%	$63.5M+285.6%	$16.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$37K-50.7%	$75K+188.5%	$26K-95.6%	$588K	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$9.9M-72.7%	$36.3M+429.0%	$6.9M-43.3%	$12.1M-1.4%	$12.3M-8.1%	$13.4M
Current Liabilities	$9.4M-73.5%	$35.4M+415.4%	$6.9M-36.1%	$10.8M+10.9%	$9.7M-20.2%	$12.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$61.2M+87.9%	$32.6M-15.8%	$38.7M-31.1%	$56.1M-42.2%	$97.2M+34.7%	$72.1M
Retained Earnings	-$412.3M-3.8%	-$397.0M-18.6%	-$334.7M-8.8%	-$307.7M-15.5%	-$266.4M-19.4%	-$223.1M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$71.1M-11.6%	$80.5M-10.0%	$89.5M+50.5%	$59.4M-13.7%	$68.9M+17.2%	$58.8M-8.9%	$64.6M+61.1%	$40.1M
Current Assets	$58.2M-13.0%	$66.9M-11.7%	$75.8M+66.6%	$45.5M-16.4%	$54.4M+26.8%	$42.9M-11.1%	$48.3M+111.2%	$22.9M
Cash & Equivalents	$4.6M+59.6%	$2.9M-80.5%	$14.7M+193.9%	$5.0M-42.8%	$8.7M+86.8%	$4.7M-68.5%	$14.8M+99.0%	$7.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$37K+15.6%	$32K-62.8%	$86K+8.9%	$79K+5.3%	$75K+7.1%	$70K+100.0%	$35K+34.6%	$26K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$9.9M+13.9%	$8.7M-5.7%	$9.2M-8.7%	$10.1M-72.2%	$36.3M-21.7%	$46.4M+248.0%	$13.3M+98.4%	$6.7M
Current Liabilities	$9.4M+16.2%	$8.1M-5.1%	$8.5M-8.3%	$9.3M-73.8%	$35.4M-23.7%	$46.4M+248.0%	$13.3M+98.4%	$6.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$61.2M-14.7%	$71.8M-10.5%	$80.2M+62.7%	$49.3M+51.5%	$32.6M+162.5%	$12.4M-75.8%	$51.2M+53.5%	$33.4M
Retained Earnings	-$412.3M-3.1%	-$400.0M-2.6%	-$389.8M-2.1%	-$381.8M+3.8%	-$397.0M-3.1%	-$384.9M-11.7%	-$344.7M-1.3%	-$340.4M

CRVS Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$32.8M-29.0%	-$25.4M-6.2%	-$23.9M+11.4%	-$27.0M+26.4%	-$36.7M-5.6%	-$34.8M
Capital Expenditures	$174K	N/A	$34K-87.4%	$269K+5280.0%	$5K-93.4%	$76K
Free Cash Flow	-$33.0M	N/A	-$24.0M+12.2%	-$27.3M+25.7%	-$36.7M-5.4%	-$34.9M
Investing Cash Flow	-$7.8M+71.6%	-$27.5M-276.8%	$15.5M+166.8%	-$23.3M-208.0%	$21.6M-51.8%	$44.8M
Financing Cash Flow	$36.4M-25.7%	$49.0M+524.2%	$7.9M	$0-100.0%	$62.2M+4644.9%	$1.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$9.2M+3.9%	-$9.6M-65.6%	-$5.8M+30.1%	-$8.3M+2.4%	-$8.5M-33.9%	-$6.3M-15.3%	-$5.5M-6.3%	-$5.2M
Capital Expenditures	$25K	$0-100.0%	$113K+213.9%	$36K	N/A	N/A	N/A	N/A
Free Cash Flow	-$9.2M+3.7%	-$9.6M-62.4%	-$5.9M+29.0%	-$8.3M	N/A	N/A	N/A	N/A
Investing Cash Flow	$10.9M+515.6%	-$2.6M+87.1%	-$20.3M-578.5%	$4.2M+169.8%	-$6.1M-56.4%	-$3.9M+77.8%	-$17.5M-249957.1%	-$7K
Financing Cash Flow	$20K-94.4%	$360K-99.0%	$35.8M+12720.8%	$279K-98.5%	$18.6M+37116.0%	$50K	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CRVS Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-25.0%+166.3pp	-191.3%-121.4pp	-69.9%+3.7pp	-73.6%-29.1pp	-44.5%-36.2pp	-8.3%
Return on Assets	-21.5%+68.9pp	-90.4%-31.1pp	-59.3%+1.2pp	-60.5%-21.0pp	-39.5%-32.5pp	-7.0%
Current Ratio	6.21+4.7	1.54-2.5	4.070.0	4.06-3.3	7.36+3.6	3.73
Debt-to-Equity	0.16-1.0	1.12+0.9	0.18-0.0	0.22+0.1	0.13-0.1	0.19
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-14.1%-4.2pp	-10.0%-40.8pp	30.8%	N/A	-324.1%-315.8pp	-8.3%+8.8pp	-17.1%
Return on Assets	N/A	-12.6%-3.7pp	-8.9%-34.5pp	25.6%	N/A	-68.4%-61.8pp	-6.6%+7.6pp	-14.2%
Current Ratio	6.21-2.1	8.29-0.6	8.91+4.0	4.90+3.4	1.54+0.6	0.92-2.7	3.62+0.2	3.40
Debt-to-Equity	0.16+0.0	0.120.0	0.12-0.1	0.20-0.9	1.12-2.6	3.74+3.5	0.26+0.1	0.20
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Prothena PRTA

$539.9M

Replimune Group REPL

$628.4M

Alumis Inc ALMS

$2.9B

Iteos Therapeutics, Inc. ITOS

$448.7M

Astria Therapeutics Inc ATXS

$718.1M

Frequently Asked Questions

Is Corvus Pharmaceu profitable?

No, Corvus Pharmaceu (CRVS) reported a net income of -$15.3M in fiscal year 2025.

What is Corvus Pharmaceu's EBITDA?

Corvus Pharmaceu (CRVS) had EBITDA of -$42.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Corvus Pharmaceu's return on equity (ROE)?

Corvus Pharmaceu (CRVS) has a return on equity of -25.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Corvus Pharmaceu's free cash flow?

Corvus Pharmaceu (CRVS) generated -$33.0M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Corvus Pharmaceu's operating cash flow?

Corvus Pharmaceu (CRVS) generated -$32.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Corvus Pharmaceu's total assets?

Corvus Pharmaceu (CRVS) had $71.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Corvus Pharmaceu's capital expenditures?

Corvus Pharmaceu (CRVS) invested $174K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Corvus Pharmaceu spend on research and development?

Corvus Pharmaceu (CRVS) invested $33.7M in research and development during fiscal year 2025.

How many shares does Corvus Pharmaceu have outstanding?

Corvus Pharmaceu (CRVS) had 75M shares outstanding as of fiscal year 2025.

What is Corvus Pharmaceu's current ratio?

Corvus Pharmaceu (CRVS) had a current ratio of 6.21 as of fiscal year 2025, which is generally considered healthy.

What is Corvus Pharmaceu's debt-to-equity ratio?

Corvus Pharmaceu (CRVS) had a debt-to-equity ratio of 0.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Corvus Pharmaceu's return on assets (ROA)?

Corvus Pharmaceu (CRVS) had a return on assets of -21.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Corvus Pharmaceu's cash runway?

Based on fiscal year 2025 data, Corvus Pharmaceu (CRVS) had $4.6M in cash against an annual operating cash burn of $32.8M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Corvus Pharmaceu's Piotroski F-Score?

Corvus Pharmaceu (CRVS) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Corvus Pharmaceu's earnings high quality?

Corvus Pharmaceu (CRVS) has an earnings quality ratio of 2.15x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.